MOLOGEN AG

  • WKN: A2LQ90
  • ISIN: DE000A2LQ900
  • Land: Deutschland

Nachricht vom 13.02.2018 | 16:11

MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod

MOLOGEN AG / Key word(s): Contract/Agreement
MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod

13-Feb-2018 / 16:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of an insider information pursuant to Section 17 of the regulation (EU) No. 596/2014

MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod

Berlin, 13 February 2018 - The Executive Board of biopharmaceutical company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today announced the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its lead compound lefitolimod. The signed agreement is conditional upon an initial payment of EUR 3 million received by MOLOGEN. ONCOLOGIE is an oncology-focused drug development company with headquarters in Boston, US, and operations in Shanghai. The company is backed by top-tier international investors and has the objective to develop novel personalized medicines in the field of immuno-oncology. The signed agreement with ONCOLOGIE includes the development, manufacture and commercialization of lefitolimod in China and a planned global co-development program.

As previously announced, MOLOGEN had started negotiations on such a deal with the Chinese iPharma. After a certain exclusivity period had expired, MOLOGEN opened the licencing process also for additional parties. Discussions and negotiations with ONCOLOGIE have now been successfully completed and the deal could be signed. The terms of the signed agreement with ONCOLOGIE define development, manufacture and commercialization of lefitolimod in China and a planned global co-development program.

The contract comprises two parts: First, a license agreement including sublicense rights under which MOLOGEN grants ONCOLOGIE an exclusive license for the development, manufacturing and commercialization for MOLOGEN's lead compound lefitolimod in the following territory: China, Hong Kong and Macao, Taiwan and Singapore. Second, a commitment for global co-development leveraging novel biomarker plans from ONCOLOGIE. MOLOGEN is to receive an initial payment of EUR 3 million as well as a EUR 2 million equity investment by ONCOLOGIE within the next 12 months.
Besides the initial payment and the equity investment, the parties agreed on further development and commercialisation milestones. They are due upon reaching predefined development steps as well as market approval. In addition, commercial milestones are defined which are due upon reaching certain sales thresholds. The total payments can amount to above EUR 100 million and will be paid over several years. Additionally, MOLOGEN will receive low double digit royalties on sales. MOLOGEN and ONCOLOGIE will share the economic returns from global joint development pursuant to both parties' contributions.

All costs relating to development, registration, marketing and commercialization of lefitolimod in the territory are to be covered by ONCOLOGIE.

- End of the ad-hoc notification -

Contact

Claudia Nickolaus

Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

 

Note about risk for future predictions

Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.


13-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Aves One AG: kursziel deutlich angehoben

Die Aves One AG ist im Geschäftsjahr 2017 abermals dynamisch gewachsen. Der Umsatz stieg um fast 90 % auf über 53 Mio. EUR an. Der jetzt gemeldete Erwerb von umfangreichen Rail-Assets (VTG/Nacco-Deal) soll zu weiteren Steigerungen beitragen. Wir erwarten weiteres Wachstum von über 40% im laufenden Jahr sowie einen dynamischen Anstieg in den Folgejahren. Das Ziel von 1 Mrd. Assets und Managment könnte bereits 2019 und damit ein Jahr früher erreicht werden. Unsere Analysten sind vom VTG/Nacco-Deal überzeugt und haben das Kursziel deutlich auf 12,10 Euro erhöht (bisher 9,10 Euro).

Aktueller Webcast

EQS Group AG

Half-yearly financial statements 2018

16. August 2018

Aktuelle Research-Studie

FinLab AG

Original-Research: FinLab AG (von GBC AG): BUY

17. August 2018